Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III
The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood.
You may also be interested in...
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
Novartis is to invest $35m in stem cell therapy developer Gamida Cell in exchange for a 15% stake of the Israeli firm and an option to acquire the company.